NCT00728000 2019-11-25
Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma
University of Cincinnati
Phase 2 Withdrawn
Clinical Trials
5 trialsNCT02689336 2019-09-09
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
Washington University School of Medicine
Phase 2 Withdrawn
NCT01928160 2015-07-13
Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn
NCT02034097 2014-05-19
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer
GlaxoSmithKline
Phase 2 Withdrawn
NCT01013506 2013-05-23
Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn